Publicaciones en las que colabora con JUAN VICENTE ESPLUGUES MOTA (41)

2024

  1. Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease

    Journal of Pathology, Vol. 262, Núm. 3, pp. 377-389

  2. Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation

    Biomedicine and Pharmacotherapy, Vol. 178

  3. Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD

    Biomedicines, Vol. 12, Núm. 7

2023

  1. Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease

    Biomedicine and Pharmacotherapy, Vol. 167

2022

  1. Down-Regulation of the Longevity-Associated Protein SIRT1 in Peripheral Blood Mononuclear Cells of Treated HIV Patients

    Cells, Vol. 11, Núm. 3

  2. Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less

    Cell Death and Disease, Vol. 13, Núm. 4

  3. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

    Biomedicines, Vol. 10, Núm. 1

2021

  1. Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment

    Cells, Vol. 10, Núm. 2

  2. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved

    Cells, Vol. 10, Núm. 7

  3. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?

    Journal of Pathology, Vol. 254, Núm. 3, pp. 216-228

2020

  1. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells

    Gut, Vol. 69, Núm. 5, pp. 920-932

  2. p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral blood mononuclear cells of HIV-patients exposed to non-nucleoside reverse transcriptase inhibitors

    Antiviral Research, Vol. 178

2019

  1. Mitophagy in human astrocytes treated with the antiretroviral drug Efavirenz: Lack of evidence or evidence of the lack

    Antiviral Research, Vol. 168, pp. 36-50

2018

  1. Role of p62/SQSTM1 beyond autophagy: a lesson learned from drug-induced toxicity in vitro

    British Journal of Pharmacology, Vol. 175, Núm. 3, pp. 440-455

2017

  1. Cardiovascular toxicity of abacavir: A clinical controversy in need of a pharmacological explanation

    AIDS, Vol. 31, Núm. 13, pp. 1781-1795

  2. Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects

    European Journal of Pharmacology, Vol. 812, pp. 163-173

  3. Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress

    British Journal of Pharmacology, Vol. 174, Núm. 23, pp. 4409-4429

2016

  1. Endoplasmic reticulum and mitochondria: Independent roles and crosstalk in fatty liver diseases and hepatic inflammation

    Current Pharmaceutical Design, Vol. 22, Núm. 18, pp. 2607-2618

  2. Proton pump inhibitors display antitumor effects in barrett's adenocarcinoma cells

    Frontiers in Pharmacology, Vol. 7, Núm. NOV, pp. 1-1

  3. The heat stress response and diabetes: More room for mitochondrial implication

    Current Pharmaceutical Design, Vol. 22, Núm. 18, pp. 2619-2639